📊 ZLAB Key Takeaways
Is Zai Lab Ltd (ZLAB) a Good Investment?
Zai Lab is a loss-making pharmaceutical company with improving financial trends but weak operational fundamentals. While net losses are contracting and the balance sheet is strong with $679.6M cash, significant operating losses, negative free cash flow of -$158.9M, and flat revenue growth (+0.7% YoY) indicate the company remains dependent on clinical pipeline success for viability.
Why Buy Zai Lab Ltd Stock? ZLAB Key Strengths
- Strong cash position of $679.6M with minimal debt (0.00x debt/equity ratio)
- Improving profitability trend with net loss up 31.7% YoY despite operational challenges
- Healthy liquidity with current ratio of 2.45x and quick ratio of 2.27x
ZLAB Stock Risks: Zai Lab Ltd Investment Risks
- Severe operating losses of -$229.4M with -49.9% operating margin
- Negative free cash flow of -$158.9M indicating ongoing cash burn and unsustainable burn rate
- Stagnant revenue growth at only +0.7% YoY showing limited market traction and commercialization success
- Heavy dependence on pharmaceutical pipeline execution with no visibility into clinical trial success rates or approval timelines
Key Metrics to Watch
- Quarterly revenue growth rate and product commercialization milestones
- Monthly cash burn rate and runway remaining at current burn levels
- Operating cash flow improvement trajectory toward breakeven
- Clinical trial progress and regulatory approval status for key pipeline assets
Zai Lab Ltd (ZLAB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.45x current ratio provides a solid financial cushion.
ZLAB Profit Margin, ROE & Profitability Analysis
ZLAB vs Healthcare Sector: How Zai Lab Ltd Compares
How Zai Lab Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zai Lab Ltd Stock Overvalued? ZLAB Valuation Analysis 2026
Based on fundamental analysis, Zai Lab Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zai Lab Ltd Balance Sheet: ZLAB Debt, Cash & Liquidity
ZLAB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zai Lab Ltd's revenue has grown significantly by 217% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.35 indicates the company is currently unprofitable.
ZLAB Revenue Growth, EPS Growth & YoY Performance
ZLAB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $101.8M | -$36.0M | $-0.03 |
| Q2 2025 | $100.1M | -$40.7M | $-0.04 |
| Q1 2025 | $87.1M | -$48.4M | $-0.04 |
| Q3 2024 | $69.2M | -$41.7M | $-0.04 |
| Q2 2024 | $68.9M | -$49.1M | $-0.08 |
| Q1 2024 | $62.8M | -$49.1M | $-0.05 |
| Q3 2023 | $57.0M | -$49.1M | $-0.07 |
| Q2 2023 | $47.6M | -$49.1M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zai Lab Ltd Dividends, Buybacks & Capital Allocation
ZLAB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zai Lab Ltd (CIK: 0001704292)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZLAB
What is the AI rating for ZLAB?
Zai Lab Ltd (ZLAB) has an AI rating of HOLD with 38% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZLAB's key strengths?
Claude: Strong cash position of $679.6M with minimal debt (0.00x debt/equity ratio). Improving profitability trend with net loss up 31.7% YoY despite operational challenges.
What are the risks of investing in ZLAB?
Claude: Severe operating losses of -$229.4M with -49.9% operating margin. Negative free cash flow of -$158.9M indicating ongoing cash burn and unsustainable burn rate.
What is ZLAB's revenue and growth?
Zai Lab Ltd reported revenue of $460.2M.
Does ZLAB pay dividends?
Zai Lab Ltd does not currently pay dividends.
Where can I find ZLAB SEC filings?
Official SEC filings for Zai Lab Ltd (CIK: 0001704292) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZLAB's EPS?
Zai Lab Ltd has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZLAB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zai Lab Ltd has a HOLD rating with 38% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZLAB stock overvalued or undervalued?
Valuation metrics for ZLAB: ROE of -24.5% (sector avg: 15%), net margin of -38.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZLAB stock in 2026?
Our dual AI analysis gives Zai Lab Ltd a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZLAB's free cash flow?
Zai Lab Ltd's operating cash flow is $-150.8M, with capital expenditures of $8.1M. FCF margin is -34.5%.
How does ZLAB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -38.1% (avg: 12%), ROE -24.5% (avg: 15%), current ratio 2.45 (avg: 2).